{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:26:46Z","timestamp":1787671606221,"version":"build-2736575974"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","funder":[{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"crossref","award":["R03-HS029699"],"award-info":[{"award-number":["R03-HS029699"]}],"id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["J Am Acad Orthop Surg","JAAOS"],"published-print":{"date-parts":[[2026,2,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Clinical guidelines recommend low-molecular-weight heparin (enoxaparin) to prevent venous thromboembolism in orthopaedic trauma patients. However, a large trial recently found aspirin noninferior to enoxaparin in preventing death and pulmonary embolism in this population. We modeled cost implications for the United States healthcare system if aspirin replaced enoxaparin as the standard of care for thromboprophylaxis in orthopaedic trauma patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The modeling compared spending under two scenarios: continued use of enoxaparin versus switching to aspirin. The model included fracture incidence estimates from the National Inpatient Sample and dose and duration data from the clinical trial. We derived medication costs from current market prices across payer types and care settings (ie, inpatient and postdischarge prescriptions). The model incorporates uncertainty around each parameter based on calculated standard errors and generates bootstrapped estimates of costs and cost savings disaggregated by the payer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The results indicated that prescribing enoxaparin for thromboprophylaxis to more than 600,000 fracture patients costs $162.7 million annually, whereas thromboprophylaxis with aspirin would cost $1.6 million annually. Spending on thromboembolic events totals $210.7 million under the enoxaparin scenario and $222.1 million with aspirin. Overall, aspirin for thromboprophylaxis in fracture patients would yield annual savings of $149.7 million (95% credible interval: $97 to $208 million) compared with enoxaparin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Our findings suggest that a widespread switch from enoxaparin thromboprophylaxis to aspirin would lead to more than $100 million in annual cost savings in the United States alone. Insurers stand to benefit most from this practice change. However, patients, especially those without insurance, would realize considerable savings from aspirin thromboprophylaxis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Level of Evidence:<\/jats:title>\n                    <jats:p>Level 1, Economic.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5435\/jaaos-d-24-01331","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T17:00:10Z","timestamp":1752685210000},"page":"e437-e446","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Cost Savings of Switching to Aspirin for Thromboprophylaxis in Orthopaedic Trauma Patients: A Budget Impact Analysis"],"prefix":"10.5435","volume":"34","author":[{"given":"Joseph F.","family":"Levy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert V.","family":"O'Toole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah M.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliott R.","family":"Haut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine P.","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renan C.","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan N.","family":"O'Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"METRC","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Major Extremity Trauma Research Consortium (METRC) Corporate Author","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,7,9]]},"reference":[{"key":"R1-20260515","first-page":"CD008303","article-title":"Thromboprophylaxis for trauma patients","volume":"2013","author":"Barrera","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"R2-20260515","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/01.sla.0000137138.40116.6c","article-title":"Thromboembolism after trauma: An analysis of 1602 episodes from the American College of Surgeons National Trauma Data Bank","volume":"240","author":"Knudson","year":"2004","journal-title":"Ann Surg"},{"key":"R3-20260515","first-page":"994","article-title":"Predictors of posttraumatic deep vein thrombosis (DVT): Hospital practice versus patient factors-an analysis of the National Trauma Data Bank (NTDB)","volume":"66","author":"Haut","year":"2009","journal-title":"J Trauma"},{"key":"R4-20260515","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/1062860613494751","article-title":"Using AHRQ patient safety indicators to detect postdischarge adverse events in the Veterans Health Administration","volume":"29","author":"Mull","year":"2014","journal-title":"Am J Med Qual"},{"key":"R5-20260515","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.jamcollsurg.2010.07.007","article-title":"Validity of selected patient safety indicators: Opportunities and concerns","volume":"212","author":"Kaafarani","year":"2011","journal-title":"J Am Coll Surg"},{"key":"R6-20260515","doi-asserted-by":"crossref","first-page":"e278S","DOI":"10.1378\/chest.11-2404","article-title":"Prevention of VTE in orthopedic surgery patients: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Falck-Ytter","year":"2012","journal-title":"Chest"},{"key":"R7-20260515","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1097\/BOT.0000000000000387","article-title":"Venous thromboembolism prophylaxis in orthopaedic trauma patients: A survey of OTA member practice patterns and OTA expert panel recommendations","volume":"29","author":"Sagi","year":"2015","journal-title":"J Orthop Trauma"},{"key":"R8-20260515","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/00005373-200207000-00032","article-title":"Practice management guidelines for the prevention of venous thromboembolism in trauma patients: The EAST practice management guidelines work group","volume":"53","author":"Rogers","year":"2002","journal-title":"J Trauma"},{"key":"R9-20260515","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jss.2019.12.023","article-title":"The national burden of orthopedic injury: Cross-sectional estimates for trauma system planning and optimization","volume":"249","author":"Jarman","year":"2020","journal-title":"J Surg Res"},{"issue":"2 Suppl","key":"R10-20260515","doi-asserted-by":"crossref","first-page":"7S","DOI":"10.1378\/chest.1412S3","article-title":"Executive summary: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Guyatt","year":"2012","journal-title":"Chest"},{"key":"R11-20260515","doi-asserted-by":"crossref","first-page":"750","DOI":"10.5435\/JAAOS-D-19-00409","article-title":"Venous thromboembolism prophylaxis after pelvic and acetabular fractures: A survey of orthopaedic surgeons' current practices","volume":"28","author":"Lim","year":"2020","journal-title":"J Am Acad Orthop Surg"},{"key":"R12-20260515","doi-asserted-by":"crossref","first-page":"e001070","DOI":"10.1136\/tsaco-2022-001070","article-title":"Survey of venous thromboembolism prophylaxis in trauma patients: Current prescribing practices and concordance with clinical practice guidelines","volume":"8","author":"Alexander","year":"2023","journal-title":"Trauma Surg Acute Care Open"},{"key":"R13-20260515","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/jhm.2282","article-title":"Patient preferences regarding pharmacologic venous thromboembolism prophylaxis","volume":"10","author":"Wong","year":"2015","journal-title":"J Hosp Med"},{"key":"R14-20260515","doi-asserted-by":"crossref","first-page":"105446","DOI":"10.1016\/j.yrtph.2023.105446","article-title":"Scientific considerations in the regulatory approval of generic (or biosimilar) version of enoxaparin sodium\u2013a lifesaving carbohydrate polymer","volume":"143","author":"Iqbal","year":"2023","journal-title":"Regul Toxicol Pharmacol"},{"key":"R15-20260515","doi-asserted-by":"crossref","first-page":"S328","DOI":"10.1016\/j.arth.2024.01.050","article-title":"Trends in deep vein thrombosis prophylaxis after total knee arthroplasty: 2016 to 2021","volume":"39","author":"Dubin","year":"2024","journal-title":"J Arthroplasty"},{"key":"R16-20260515","doi-asserted-by":"crossref","first-page":"e041845","DOI":"10.1136\/bmjopen-2020-041845","article-title":"PREVENTion of CLots in orthopaedic trauma (PREVENT CLOT): A randomised pragmatic trial protocol comparing aspirin versus low-molecular-weight heparin for blood clot prevention in orthopaedic trauma patients","volume":"11","author":"O'Toole","year":"2021","journal-title":"BMJ Open"},{"key":"R17-20260515","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa2205973","article-title":"Aspirin or low-molecular-weight heparin for thromboprophylaxis after a fracture","volume":"388","author":"O'Toole","year":"2023","journal-title":"N Engl J Med"},{"key":"R18-20260515","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/TA.0000000000004226","article-title":"Risk-stratified thromboprophylaxis effects of aspirin versus low-molecular-weight heparin in orthopaedic trauma patients: a secondary analysis of the PREVENT CLOT trial","volume":"96","author":"O'Hara","year":"2024","journal-title":"J Trauma Acute Care Surg"},{"key":"R19-20260515","doi-asserted-by":"crossref","first-page":"e016676","DOI":"10.1136\/bmjopen-2017-016676","article-title":"Patient preferences for venous thromboembolism prophylaxis after injury: A discrete choice experiment","volume":"7","author":"Haac","year":"2017","journal-title":"BMJ Open"},{"key":"R20-20260515","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/TA.0000000000001771","article-title":"Post-discharge adherence with venous thromboembolism prophylaxis after orthopedic trauma: Results from a randomized controlled trial of aspirin versus low molecular weight heparin","volume":"84","author":"Haac","year":"2018","journal-title":"J Trauma Acute Care Surg"},{"key":"R21-20260515","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.thromres.2017.10.012","article-title":"Exploring the impact of route of administration on medication acceptance in hospitalized patients: Implications for venous thromboembolism prevention","volume":"160","author":"Popoola","year":"2017","journal-title":"Thromb Res"},{"key":"R22-20260515","doi-asserted-by":"crossref","first-page":"392","DOI":"10.2146\/ajhp161057","article-title":"Nonadministration of medication doses for venous thromboembolism prophylaxis in a cohort of hospitalized patients","volume":"75","author":"Popoola","year":"2018","journal-title":"Am J Health Syst Pharm"},{"key":"R23-20260515","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1056\/NEJMe2214045","article-title":"Thromboprophylaxis after extremity fracture\u2014time for aspirin?","volume":"388","author":"Costa","year":"2023","journal-title":"N Engl J Med"},{"key":"R24-20260515","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1093\/eurheartj\/ehad098","article-title":"Aspirin for venous thromboprophylaxis after fracture: Ready for prime time?","volume":"44","author":"Vergallo","year":"2023","journal-title":"Eur Heart J"},{"key":"R25-20260515","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: Second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"key":"R26-20260515","doi-asserted-by":"crossref","first-page":"e001511","DOI":"10.1136\/tsaco-2024-001511","article-title":"Venous thromboembolism prophylaxis prescribing patterns for patients with orthopedic trauma: A clinical vignette survey","volume":"9","author":"O'Hara","year":"2024","journal-title":"Trauma Surg Acute Care Open"},{"issue":"suppl 3","key":"R27-20260515","first-page":"304","article-title":"Clinical assessment of venous thromboembolic risk in surgical patients","volume":"17","author":"Caprini","year":"1991","journal-title":"Semin Thromb Hemost"},{"key":"R28-20260515","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/BOT.0000000000001451","article-title":"Is the Caprini score predictive of venothromboembolism events in orthopaedic fracture patients?","volume":"33","author":"Dashe","year":"2019","journal-title":"J Orthop Trauma"},{"key":"R29-20260515","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.jtha.2023.02.018","article-title":"Decision-analysis modeling of effectiveness and cost-effectiveness of pharmacologic thromboprophylaxis for surgical inpatients using variable risk assessment models or other strategies","volume":"21","author":"Davis","year":"2023","journal-title":"J Thromb Haemost"},{"key":"R30-20260515","doi-asserted-by":"crossref","first-page":"S134","DOI":"10.1016\/j.arth.2020.11.035","article-title":"A comprehensive monetary analysis of inpatient total hip and knee arthroplasties billed to medicare by hospitals: 2011-2017","volume":"36","author":"Haglin","year":"2021","journal-title":"J Arthroplasty"},{"key":"R31-20260515","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/jth.13677","article-title":"Anticoagulation in patients with isolated distal deep vein thrombosis: A meta-analysis","volume":"15","author":"Franco","year":"2017","journal-title":"J Thromb Haemost"}],"container-title":["Journal of the American Academy of Orthopaedic Surgeons"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.5435\/JAAOS-D-24-01331","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:48:32Z","timestamp":1787669312000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.5435\/JAAOS-D-24-01331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,9]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5435\/jaaos-d-24-01331","relation":{},"ISSN":["1067-151X","1940-5480"],"issn-type":[{"value":"1067-151X","type":"print"},{"value":"1940-5480","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,9]]},"assertion":[{"value":"2024-11-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}